Depression in Adolescents: Screening, Diagnosis, and Management (GLAAD-PC-based notes)

Learning objectives

  • Implement a routine screening protocol for depression in children and adolescents

  • Explain the use of cognitive behavioral therapy (CBT) and interpersonal therapy (IPT) to address major depressive disorder (MDD) in adolescents

  • Outline initial treatment strategies for mild vs moderate-to-severe depression, including pharmacologic and nonpharmacologic interventions

  • Develop a safety plan for patients with increased suicidality or acute crisis using shared decision making

  • Recognize barriers to identification and treatment of adolescent depression in primary care and strategies to overcome them

  • Understand the role of primary care in referrals, collaborative care, and integration of mental health resources

  • Appreciate the impacts of the COVID-19 era on adolescent mental health and evolving evidence in treatment options

Epidemiology and burden of adolescent depression (context for practice)

  • Pre-pandemic baseline: roughly 12ext−13extextpercent12 ext{-}13 ext{ extpercent} of adolescents had depression; prevalence worldwide rose to 25extextpercent25 ext{ extpercent} later in the pandemic

  • Lifetime prevalence by age 20 (pre-2020 estimates): about 20extextpercent20 ext{ extpercent}; ~40extextpercent40 ext{ extpercent} of adults with MDD report symptom onset during adolescence

  • Early onset associated with worse adulthood outcomes: more hospitalizations for depression, self-harm, suicide; poorer physical health; worse social and occupational outcomes

  • Diagnosis gap in adolescence: ~50extextpercent50 ext{ extpercent} of adolescents with depression are diagnosed before adulthood; in primary care, up to 2/32/3 of depressed adolescents are not identified and do not receive mental health care

  • Barriers to diagnosis in primary care include: time constraints, reimbursement/coding challenges, lack of training, limited access to mental health services, functional variability in teens, and societal expectations of moodiness as “normal” adolescence

  • Provider attitudes matter: greater identification with increased training; traditional lecture-based training is less effective for improving identification; evidence supports efficient, guideline-based screening and diagnosis

  • Primary care setting is critical due to access, longitudinal relationships, and workforce shortages in mental health specialists

Suicide and risk in adolescents (clinical urgency)

  • Suicide is the second leading cause of death in US youths aged 10–19

  • 2017 US high school survey: 16extextpercent16 ext{ extpercent} seriously considered suicide; 13extextpercent13 ext{ extpercent} made a plan; 8extextpercent8 ext{ extpercent} attempted suicide in the prior 12 months

  • Among adolescents with MDD, about 20extextpercent20 ext{ extpercent} attempt suicide

  • Among those who complete suicide, about 50extextpercent50 ext{ extpercent} had a diagnosed depression (note: many cases are not diagnosed)

  • 2019 data: ~三千 deaths by suicide in ages 10–19; rate higher in males (≈3×) than females; white adolescents higher than Black adolescents, but the gap is narrowing with rising rates in Black adolescents, especially females; American Indians have the highest rate (~13/100,00013/100{,}000)

  • LGBTQ+ youth disproportionately affected: among 12–14 years, 24extextpercent24 ext{ extpercent} of deaths; among 15–17 years, 16extextpercent16 ext{ extpercent}

  • Pandemic-era changes (2020–2022): female ED visits for suspected suicide attempts rose by ≈50extextpercent50 ext{ extpercent} vs males (≈3extextpercent3 ext{ extpercent}); LGBTQ+ youth show higher risk; supportive school policies reduce suicide-related behaviors

  • LGBTQ+-inclusive school policies are protective for LGBTQ and heterosexual students

Why primary care?

  • Most accessible setting for teens; ongoing relationship with patient and family

  • Increasing need due to shortage of mental health specialists; initial management often occurs in primary care

Screening guidelines and tools (how we identify depression in youth)

  • USPSTF (2022 update): screen all youths aged 12ext−1812 ext{-}18 for major depressive disorder; screen for anxiety in the same age group (new in USPSTF guidance)

    • Depression: ages 12ext−1812 ext{-}18; anxiety: ages 8ext−118 ext{-}11 noted as not recommended by USPSTF for those age groups (evidence inconclusive for younger ages)

  • GLAAD-PC (Guidelines for Adolescent Depression in Primary Care): two key articles in Pediatrics; free toolkit available at gladpc.org

    • Screening: all youths ≥1212 at every annual visit; screen at interim visits for depression risk factors

    • Risk factors include: other psychological disorders, accelerated puberty, LGBTQ status, prior suicide attempt, internet addiction, parental/family conflict, substance use, social media use; urban design factors like limited access to nature may also be relevant

    • Screening workflow: screening, diagnosis, and management in a structured algorithm

  • Screening tools: validated depression screening tools (PHQ-9 for adolescents; PHQ-A; Beck Depression Inventory; CES-D, etc.)

    • USPSTF did not endorse one specific tool over another; PHQ-9/PHQ-A and BDI are among most studied and widely used

    • Tool selection should consider age, reading level, time, and whether parent input is included (parent input increases sensitivity)

    • Screening can be digital (during check-in), paper-based, or via clinical interview

  • PHQ-2: two-question screen for the past two weeks; a negative screen requires two negative answers

    • If positive, proceed to PHQ-9 or PHQ-A; note that PHQ-2 does not assess suicidality, so it may miss suicidality in some teens

  • PHQ-9 (or PHQ-A): includes the suicide item; provides overall depression severity (0–27) and a diagnostic classification (none/minimal, mild, moderate, moderately severe, severe)

  • DSM-5 criteria for depressive disorder helps frame diagnosis (see next section)

Case: Donna (15-year-old) – screening and initial care considerations

  • Presentation: annual wellness visit; multiple risk factor screenings (STI risk, pregnancy risk counseling, HPV vaccination update); BMI 28; headaches and musculoskeletal complaints; time overrun for visit

  • Costs of not screening for depression include poorer functioning at work/school/home, substance use, early parenthood, harmful behaviors, and suicide risk

  • Suicide risk data reinforce importance of primary care screening and proactive management

  • USPSTF & GLAAD-PC alignment: screen all 12–18 at every visit; screen for anxiety as new USPSTF element (though not the focus here)

Presentation and assessment of adolescent depression (clinical features)

  • Depression in adolescents can present as mood irritability rather than outright sadness; irritability is a common substitute for depressed mood

  • Common symptoms: irritability, fatigue, poor concentration, withdrawal from activities, weight/appetite changes, sleep disturbance, somatic complaints (headache/musculoskeletal pain), social withdrawal

  • Important to differentiate normal teen moodiness from depressive disorder by examining: duration, persistence, and impact on functioning (school, home, social life)

  • DSM-5 criteria for MDD in youth emphasize either depressed mood or irritability plus at least four additional symptoms (for a total of 5 symptoms, including the primary one, most of the day, nearly every day, for at least 2 weeks)

    • Weight/appetite changes, sleep disturbance, fatigue or loss of energy, feelings of worthlessness or excessive guilt, diminished ability to think or concentrate, psychomotor agitation/retardation, recurrent thoughts of death or suicidality

  • Medical and medication differential diagnoses to consider (masquerading causes): thyroid disease, anemia, medications (including contraceptives), isotretinoin, sleep disorders; screen for comorbid ADHD, anxiety, substance use, eating disorders

  • Other depressive disorders to consider in youth: persistent depressive disorder (PDD, dysthymia) – in adolescents, duration criteria can be shorter than adults; premenstrual dysphoric disorder; depression due to medical conditions; substance/medication-induced depressive disorder

Glad-PC assessment box: steps for evaluation

  • If not already screened, perform systematic depression assessment; interview both patient and parents separately when possible

  • Interview patient alone to assess safety and suicide risk

  • Assess for safety risks and plan accordingly

Management overview (severity-driven approach)

  • Key: safety planning is essential for all adolescents with depression; use collaborative safety plans; avoid old “suicide safety contracts” due to lack of collaboration and potential harm to patient-physician relationship

  • Safety planning elements (collaborative, during periods of stability):

    • Make home as safe as reasonably possible (remove firearms, medications, etc. as feasible)

    • Regularly ask about thoughts of suicide; asking about suicidality does not increase risk

    • Identify warning signs and triggers

    • Outline actions to take immediately (breathing exercises, physical activity, other coping strategies)

    • Identify social settings to go to when overwhelmed (e.g., Starbucks, library, friend’s house)

    • List people to call (best friend, parent, therapist, hospital, crisis line 988)

    • Environmental safety steps and the most important personal reason for living

    • Have a written plan readily accessible when crisis arises

  • Emergency planning and safety planning are central to care; 988 is the national crisis line/text/chat option in the US (former Lifeline)

  • Ongoing suicide risk monitoring and documentation in the medical record

Mild depression in adolescents: initial management (GLAAD-PC guidance)

  • Case example: Brenda, 12-year-old with fatigue/irritability; PHQ-9 score of 6 (mild depression)

  • First-line approach for new-onset, very mild depression: active support and monitoring for 6–8 weeks; not necessarily immediate psychotherapy; goal-directed, concrete actions are emphasized

  • Key components of active support and monitoring:

    • Patient and family education about depression and expected course

    • Linkage to community resources and peer support groups

    • Encouragement of school activities and increased exercise

    • Lifestyle-focused strategies with specific, observable goals (e.g., frequency and type of pleasurable activities, structured exercise, extracurriculars)

  • Estimated natural improvement with active support and monitoring: about 20extextpercent20 ext{ extpercent} of adolescents improve with this approach without formal therapy

  • Incorporation of lifestyle therapy (2023 evidence):

    • Diet: Increased intake of fruits, vegetables, fish, olive oil, nuts, legumes; dietary fiber linked to lower depression risk (adult: ~10extextpercent10 ext{ extpercent} decrease; adolescent: up to 60extextpercent60 ext{ extpercent} lower odds with dietary fiber; dose-response: +5 g fiber associated with ~5 ext{ extpercent} decrease in risk)

    • Omega-3 fatty acids and vitamin D/ folate if indicated

    • Exercise: Aerobic exercise beneficial for depression; goal is 60extminutes/day60 ext{ minutes/day}; yoga may help with anxiety if practiced regularly (≥4 days/week for at least 6 weeks)

    • Sleep: 9–11 hours; screen time <2 hours/day; nature exposure is particularly impactful in lower SES and densely populated areas; music therapy shows potential

  • If not improved after 6–8 weeks, or if depression is moderate–severe, escalate treatment (see below)

Moderate to severe depression: psychotherapy and pharmacotherapy

  • Core psychotherapies with evidence specifically in adolescents: CBT and IPT-A (IPT for adolescents)

  • Rationale for psychotherapy vs pharmacology: >50% of adults with mild–moderate depression respond to psychological counseling; if no clear improvement within 6–12 weeks of counseling, consider adding medication

  • CBT (adolescent-focused):

    • Focuses on how negative thoughts lead to negative feelings and behaviors; aims to modify distorted thinking and maladaptive behaviors

    • Time-limited: typically 8–12 weeks; weekly sessions; includes between-session homework

    • Core mechanism: break the cycle of negative thoughts/withdrawal by challenging beliefs and increasing engagement in positive activities

  • IPT-A (interpersonal therapy for adolescents):

    • Depression linked to interpersonal context; aims to improve relationships and communication; problem-solving skills

    • Time-limited: usually 12–16 weeks; some sessions involve caregivers; phases include problem identification, skill-building, and generalization to future problems

Pharmacotherapy in adolescents (first-line medications and rationale)

  • First-line pharmacotherapy for adolescent depression: selective serotonin reuptake inhibitors (SSRIs)

  • FDA-approved SSRIs for pediatric/adolescent depression: fluoxetine, sertraline, escitalopram, citalopram (fluoxetine is the most studied and often first-line; long half-life is advantageous for adherence)

  • Black box warning and risk communication:

    • FDA labeling warning (2004) noted increased spontaneous reports of suicidal thoughts/attempts in youths on antidepressants vs those not on antidepressants, but no suicides occurred in trials

    • This does not imply no risk; undertreatment carries substantial risk; families should be informed about potential suicidality while continuing treatment

  • Fluoxetine (FDA-approved): often preferred due to robust pediatric data and long half-life; favorable tolerability profile

  • Other FDA-approved agents for youth include sertraline, escitalopram, and citalopram; dosing is started low and titrated every 1–2 weeks to reach an effective dose; monitor for side effects and suicidality

  • Dosing strategy (general approach):

    • Start at the lowest label-approved dose; titrate every 1–2 weeks to reach target dose and then maximum tolerated dose

    • Educate families about common side effects (GI upset, sleep changes, anxiety, activation, weight changes) and timing of improvements

    • If no improvement in 6–12 weeks at an adequate dose, reassess diagnosis and consider switching or augmenting with psychotherapy

  • Key data from randomized studies:

    • The Treatment for Adolescents with Depression Study (TADS): fluoxetine alone, fluoxetine + CBT, CBT alone, and placebo over 12 weeks

    • Fluoxetine + CBT had the highest response rate (~71extextpercent71 ext{ extpercent}) at 12 weeks; fluoxetine alone ~60extextpercent60 ext{ extpercent}; CBT alone ~44extextpercent44 ext{ extpercent}; placebo lower

    • At 36 weeks, fluoxetine + CBT maintained response in ~86extextpercent86 ext{ extpercent}; fluoxetine alone ~80extextpercent80 ext{ extpercent}; CBT alone ~ almost 100% of initial responders maintained improvement

    • Overall, >80extextpercent80 ext{ extpercent} had improved and ~60extextpercent60 ext{ extpercent} achieved full remission by 36 weeks across groups

    • Combination therapy often yields better outcomes but may not be accessible for all patients

  • Monitoring and follow-up:

    • Reassess every 2–4 weeks during dose titration and earlier if safety concerns arise

    • After remission, continue treatment for 6–12 months; some data suggest 12 months reduces relapse risk more than stopping at 6 months

    • Relapse risk is highest during the first 8–12 weeks after discontinuation; ~50ext−70extextpercent50 ext{-}70 ext{ extpercent} of those who remit will have a recurrence within five years

  • When to refer to psychiatry or specialist care:

    • Moderate-to-severe depression not responding to treatment; psychosis; suicidal or homicidal ideation; new or worsening comorbid conditions; substance use disorders

  • Treatment-resistant depression (about ~30extextpercent30 ext{ extpercent} may not respond to initial treatment):

    • Switch within medication classes or switch to different classes; consider augmentation with psychotherapy if not already in place

    • Off-label considerations include switching SSRIs, duloxetine, desvenlafaxine (not demonstrated to improve depression vs placebo in youth), lithium for monopolar depression (with bipolar screening), ketamine/esketamine research ongoing, ECT after two trials, and transcranial magnetic stimulation (TMS) showing some benefit though not consistently statistically superior to sham in youth

Safety planning vs contracts; shared decision making

  • Safety planning is recommended as a collaborative tool, including:

    • Discussing warning signs, coping strategies, and steps for seeking help

    • Involving family, therapist, and clinicians in planning

    • Ensuring access to crisis lines (988), hospital, and emergency services

  • Suicide contract approach is discouraged due to lack of collaboration and potential harm to patient-therapist relationship

  • Regular inquiry about suicidality during follow-up; adjust plan as needed

Special considerations and lived realities in management

  • Age considerations:

    • Most adolescents with depression can be treated in primary care with appropriate support; some require psychiatric referral, especially for moderate-to-severe disease or therapy-resistant cases

    • Soft lower age limits for pharmacotherapy consideration (clinical judgment necessary); many guidelines target age ≥11ext–1211 ext{–}12 for initiating pharmacotherapy with proper evaluation of maturity and diagnostic certainty

  • Family engagement and school coordination are critical

  • Collaborative care models and integrated programs (e.g., Mindoula, Concert Health) help bridge PCPs with psychiatrists and therapists, often improving access and continuity of care

  • Telehealth/virtual counseling options have expanded access when in-person services are limited; quality varies and should be chosen deliberately

  • Lifestyle, social determinants, and equity: nature exposure, sleep hygiene, screen-time management, and socioeconomic factors influence depression risk and treatment response

Practical takeaways for the primary care setting

  • Always screen youths ≥1212 at annual visits for depression; consider interim screening for those with risk factors

  • If screen-positive, proceed to diagnostic assessment and safety planning; differentiate transient mood changes from clinical depression

  • Use structured tools (PHQ-9/PHQ-A, PHQ-2 as initial screen, BDI, CES-D) appropriate to age and context; confirm with DSM-5 criteria

  • For mild depression: implement active support and monitoring for 6ext−8extweeks6 ext{-}8 ext{ weeks} with goal-directed lifestyle strategies; consider CBT/IPT referral if feasible or if symptoms persist

  • For moderate-to-severe depression: discuss CBT or IPT; initiate SSRI treatment (fluoxetine often preferred) with joint consideration of psychotherapy; ensure safety planning and crisis resources are in place; arrange close follow-up (2–4 weeks during titration)

  • If remission is achieved: plan for 6–12 months of continuation therapy and gradual tapering with close monitoring for relapse

  • If inadequate response: reassess diagnosis, consider changing antidepressant (different SSRI/SNRI) or augment with psychotherapy; refer to psychiatry if warranted

  • Consider collaborative care or telehealth options to improve access to mental health professionals

Resources and references mentioned

  • GLAAD-PC guidelines and toolkit (free): gladpc.org

  • USPSTF Depression screening guidance (2022 update): emphasis on screening ages 12ext−1812 ext{-}18; anxiety screening added; suicide risk screening evidence inconclusive

  • Suicide crisis resources: 988 (call/text/chat)

  • CBT and IPT resources and referrals for adolescents (evidence-based information for families)

  • Apps and digital tools (contextual): Mind Shift CBT, Mood Kit, CBT Thought Diary, Safety Plans (Stanley–Brown safety plan), etc.

  • Collaborative care programs examples: Mindoula, Concert Health

  • Notable studies mentioned:

    • TADS (Treatment for Adolescents with Depression Study) data on fluoxetine with/without CBT, CBT alone, and placebo

    • General evidence on lifestyle modifications and dietary factors influencing depressive symptoms in youth

Quick reference (summary in bullets)

  • Screen all adolescents 12–18 at every visit; screen for anxiety too per updated USPSTF

  • Use PHQ-9/PHQ-A or equivalent; PHQ-2 can screen quickly but misses suicidality; always assess suicide risk beyond screening tool

  • Mild depression: active support and monitoring 6–8 weeks; reinforce goals, activity, sleep, exercise, social engagement

  • Moderate-to-severe depression: CBT or IPT as baseline psychotherapy; consider SSRIs (fluoxetine first-line) with careful titration and safety monitoring

  • TABS-like data support combination therapy (fluoxetine + CBT) for higher early response and sustained improvement; but access and patient preference matter

  • Safety planning is essential; replace outdated suicide contracts with collaborative safety plans

  • Continue treatment for 6–12 months after remission; anticipate relapse risk; monitor closely for early signs

  • Refer to psychiatry for treatment resistance, psychosis, suicidality, or complex comorbidity; consider ketamine/ECT/TMS in specialized settings per evolving evidence

  • Address lifestyle and social determinants (nutrition, sleep, exercise, nature, screen time) to complement therapy

  • Stay connected with families, schools, and community resources; leverage collaborative care to optimize outcomes

If you’d like, I can tailor these notes to a specific exam format (e.g., outline for a short-answer section, or a slide-ready bullet deck). Also, tell me if you want any sections expanded with more detail or condensed for a quick review card set.